Akinori Minato1, Naohiro Fujimoto2, Tatsuhiko Kubo3. 1. Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Electronic address: drunkard0428@med.uoeh-u.ac.jp. 2. Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. 3. Department of Public Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Abstract
OBJECTIVE: The efficacy of chemotherapy on UCSD is not known. This study was conducted to investigate the efficacy of cisplatin-based chemotherapy and prognosis of patients with UC with or without SD of the bladder. METHODS: Patients with invasive bladder cancer (clinical T3-4aN0M0) who were treated between March 2003 and March 2015 with 2 or 3 cycles of neoadjuvant chemotherapy followed by radical cystectomy were retrospectively evaluated. Treatment outcomes were compared for each pathologic type in UCSD and pure UC. The primary end point was pathologic response in the cystectomy specimens. Disease-free survival and overall survival were secondary end points. RESULTS: We evaluated 9 patients with UCSD and 29 patients with pure UC. In the cystectomy specimens, pathologic complete response without residual tumors was not seen in any patients with UCSD, but evident in 10 patients (34.5%) with pure UC. The proportion of pathologic downstaging was significantly lower in patients with UCSD than in those with pure UC (11.1% vs. 51.7%; P = .031). Patients with UCSD had poorer disease-free survival (P < .001) and overall survival (P = .001) than those with pure UC. On multivariate Cox regression analysis, SD in UC was an independent predictor of recurrence (hazard ratio, 4.43; 95% confidence interval, 1.44-13.6, P = .009) and mortality (hazard ratio, 3.51; 95% confidence interval, 1.11-11.1, P = .032). CONCLUSIONS: UCSD of the bladder is less sensitive to cisplatin-based chemotherapy and has poor prognosis.
OBJECTIVE: The efficacy of chemotherapy on UCSD is not known. This study was conducted to investigate the efficacy of cisplatin-based chemotherapy and prognosis of patients with UC with or without SD of the bladder. METHODS:Patients with invasive bladder cancer (clinical T3-4aN0M0) who were treated between March 2003 and March 2015 with 2 or 3 cycles of neoadjuvant chemotherapy followed by radical cystectomy were retrospectively evaluated. Treatment outcomes were compared for each pathologic type in UCSD and pure UC. The primary end point was pathologic response in the cystectomy specimens. Disease-free survival and overall survival were secondary end points. RESULTS: We evaluated 9 patients with UCSD and 29 patients with pure UC. In the cystectomy specimens, pathologic complete response without residual tumors was not seen in any patients with UCSD, but evident in 10 patients (34.5%) with pure UC. The proportion of pathologic downstaging was significantly lower in patients with UCSD than in those with pure UC (11.1% vs. 51.7%; P = .031). Patients with UCSD had poorer disease-free survival (P < .001) and overall survival (P = .001) than those with pure UC. On multivariate Cox regression analysis, SD in UC was an independent predictor of recurrence (hazard ratio, 4.43; 95% confidence interval, 1.44-13.6, P = .009) and mortality (hazard ratio, 3.51; 95% confidence interval, 1.11-11.1, P = .032). CONCLUSIONS: UCSD of the bladder is less sensitive to cisplatin-based chemotherapy and has poor prognosis.
Authors: Ahmed Ali Chughtai; Julia Pannhausen; Pia Dinger; Julia Wirtz; Ruth Knüchel; Nadine T Gaisa; Michael J Eble; Michael Rose Journal: Biomedicines Date: 2022-05-30
Authors: Michael Rose; Erik Noetzel; Jennifer Kistermann; Julian Eschenbruch; Sandra Rushrush; Lin Gan; Ruth Knüchel; Nadine T Gaisa; Edgar Dahl Journal: Cells Date: 2021-04-28 Impact factor: 6.600
Authors: Aaron A Mehus; Nicholas Bergum; Peter Knutson; Swojani Shrestha; Xu Dong Zhou; Scott H Garrett; Donald A Sens; Mary Ann Sens; Seema Somji Journal: PLoS One Date: 2020-08-21 Impact factor: 3.240
Authors: Sophie Wucherpfennig; Michael Rose; Angela Maurer; Maria Angela Cassataro; Lancelot Seillier; Ronja Morsch; Ehab Hammad; Philipp Heinrich Baldia; Thorsten H Ecke; Thomas-Alexander Vögeli; Ruth Knüchel; Nadine T Gaisa Journal: Int J Mol Sci Date: 2021-10-26 Impact factor: 5.923
Authors: Michael Rose; Angela Maurer; Julia Wirtz; Andreas Bleilevens; Tanja Waldmann; Maximilian Wenz; Marie Eyll; Mirja Geelvink; Melanie Gereitzig; Nadine Rüchel; Bernd Denecke; Elke Eltze; Edwin Herrmann; Marieta Toma; David Horst; Tobias Grimm; Stefan Denzinger; Thorsten Ecke; Thomas Alexander Vögeli; Ruth Knuechel; Jochen Maurer; Nadine T Gaisa Journal: Oncogene Date: 2020-09-25 Impact factor: 9.867